Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms
- 31 March 2004
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 43 (3) , 335-344
- https://doi.org/10.1016/j.lungcan.2003.09.011
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive daysEuropean Journal Of Cancer, 1994
- Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.Journal of Clinical Oncology, 1994
- Weekly gemcitabine in advanced or metastatic solid tumorsInvestigational New Drugs, 1994
- 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell linesBiochemical Pharmacology, 1993
- A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.Journal of Clinical Oncology, 1991
- Activity and activation of the granulocyte superoxide-generating systemBlood, 1980